Ruy M Ribeiro

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4305521/publications.pdf

Version: 2024-02-01

155 papers	8,936 citations	38742 50 h-index	49909 87 g-index
158 all docs	158 docs citations	158 times ranked	8677 citing authors

#	Article	IF	Citations
1	Complex decay dynamics of HIV virions, intact and defective proviruses, and 2LTR circles following initiation of antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	46
2	HIV influences clustering and intracellular replication of hepatitis C virus. Journal of Viral Hepatitis, 2021, 28, 334-344.	2.0	6
3	Relevance of Circulating Nucleosomes, HMGB1 and sRAGE for Prostate Cancer Diagnosis. In Vivo, 2021, 35, 2207-2212.	1.3	1
4	Modeling the Dynamics of CD4+ T Cells in HIV-1 Infection. , 2021, , 81-93.		0
5	Zika virus dynamics: Effects of inoculum dose, the innate immune response and viral interference. PLoS Computational Biology, 2021, 17, e1008564.	3.2	10
6	Infective Endocarditis as the Cause of Death: A Populationbased Study in Portugal, from 2002 to 2018. Acta Medica Portuguesa, 2021, 34, .	0.4	0
7	Serum lipids and prostate cancer. Journal of Clinical Laboratory Analysis, 2021, 35, e23705.	2.1	10
8	Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019. Open Forum Infectious Diseases, 2021, 8, ofab153.	0.9	20
9	Are Proinflammatory Cytokines Relevant for the Diagnosis of Prostate Cancer?. Anticancer Research, 2021, 41, 3067-3073.	1.1	7
10	The prostate health index (PHI) density: Are there advantages over PHI or over the prostate-specific antigen density?. Clinica Chimica Acta, 2021, 520, 133-138.	1.1	10
11	Comparison of Three Assays for Total and Free PSA Using Hybritech and WHO Calibrations. In Vivo, 2021, 35, 3431-3439.	1.3	3
12	In vivo kinetics of SARS-CoV-2 infection and its relationship with a personâ€™s infectiousness. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	108
13	Disentangling the lifespans of hepatitis C virusâ€infected cells and intracellular vRNA replicationâ€complexes during directâ€acting antiâ€viral therapy. Journal of Viral Hepatitis, 2020, 27, 261-269.	2.0	3
14	Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study. Addiction, 2020, 115, 901-913.	3.3	21
15	The impact of negative lymph nodes in the survival outcomes of pN+ patients following radical gastrectomy: the inverse lymph node ratio as a better score to study negative lymph nodes. Updates in Surgery, 2020, 72, 1031-1040.	2.0	3
16	Consumption of Alcohol and Drugs in the School Population of Sao Tome and Principe. Acta Medica Portuguesa, 2020, 33, 237.	0.4	1
17	Single hepatocytes show persistence and transcriptional inactivity of hepatitis B. JCI Insight, 2020, 5, .	5.0	17
18	Untangling the immune basis of disease susceptibility. ELife, 2020, 9, .	6.0	0

#	Article	IF	Citations
19	High-fat diet exacerbates SIV pathogenesis and accelerates disease progression. Journal of Clinical Investigation, 2019, 129, 5474-5488.	8.2	31
20	Dynamics of Simian Immunodeficiency Virus Two-Long-Terminal-Repeat Circles in the Presence and Absence of CD8⁺Cells. Journal of Virology, 2018, 92, .	3.4	17
21	Molecular Markers Distinguishing T Cell Subtypes With TSDR Strand-Bias Methylation. Frontiers in Immunology, 2018, 9, 2540.	4.8	16
22	Probabilistic control of HIV latency and transactivation by the Tat gene circuit. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12453-12458.	7.1	23
23	Modeling the immune response to HIV infection. Current Opinion in Systems Biology, 2018, 12, 61-69.	2.6	14
24	Noise Is Not Error: Detecting Parametric Heterogeneity Between Epidemiologic Time Series. Frontiers in Microbiology, 2018, 9, 1529.	3.5	1
25	Correlation Between Anti-gp41 Antibodies and Virus Infectivity Decay During Primary HIV-1 Infection. Frontiers in Microbiology, 2018, 9, 1326.	3.5	13
26	Special Issue â€œMathematical Modeling of Viral Infectionsâ€• Viruses, 2018, 10, 303.	3.3	2
27	Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7139-E7148.	7.1	16
28	The dynamics of simian immunodeficiency virus after depletion of CD8+ cells. Immunological Reviews, 2018, 285, 26-37.	6.0	12
29	Introduction to modeling viral infections and immunity. Immunological Reviews, 2018, 285, 5-8.	6.0	22
30	Emergence of resistance mutations in simian immunodeficiency virus (SIV)-infected rhesus macaques receiving non-suppressive antiretroviral therapy (ART). PLoS ONE, 2018, 13, e0190908.	2.5	1
31	Neutrophil extracellular trap production contributes to pathogenesis in SIV-infected nonhuman primates. Journal of Clinical Investigation, 2018, 128, 5178-5183.	8.2	51
32	HIV persistence in tissue macrophages of humanized myeloid-only mice during antiretroviral therapy. Nature Medicine, 2017, 23, 638-643.	30.7	233
33	Inflammatory monocytes expressing tissue factor drive SIV and HIV coagulopathy. Science Translational Medicine, 2017, 9, .	12.4	94
34	The Role of Infected Cell Proliferation in the Clearance of Acute HBV Infection in Humans. Viruses, 2017, 9, 350.	3.3	25
35	Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration. PLoS Pathogens, 2017, 13, e1006478.	4.7	45
36	Mathematics in modern immunology. Interface Focus, 2016, 6, 20150093.	3.0	29

#	Article	IF	Citations
37	Estimating biologically relevant parameters under uncertainty for experimental within-host murine West Nile virus infection. Journal of the Royal Society Interface, 2016, 13, 20160130.	3.4	39
38	Trypanosoma brucei Parasites Occupy and Functionally Adapt to the Adipose Tissue in Mice. Cell Host and Microbe, 2016, 19, 837-848.	11.0	288
39	Single-Genome Sequencing of Hepatitis C Virus in Donor-Recipient Pairs Distinguishes Modes and Models of Virus Transmission and Early Diversification. Journal of Virology, 2016, 90, 152-166.	3.4	17
40	Modeling the Effects of Morphine on Simian Immunodeficiency Virus Dynamics. PLoS Computational Biology, 2016, 12, e1005127.	3.2	19
41	Antibiotic and Antiinflammatory Therapy Transiently Reduces Inflammation and Hypercoagulation in Acutely SIV-Infected Pigtailed Macaques. PLoS Pathogens, 2016, 12, e1005384.	4.7	38
42	Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers. PLoS Pathogens, 2016, 12, e1005879.	4.7	18
43	Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b). Aids, 2015, 29, 2419-2426.	2.2	18
44	Transmitted Virus Fitness and Host T Cell Responses Collectively Define Divergent Infection Outcomes in Two HIV-1 Recipients. PLoS Pathogens, 2015, 11, e1004565.	4.7	44
45	Antibody Responses during Hepatitis B Viral Infection. PLoS Computational Biology, 2014, 10, e1003730.	3.2	60
46	Inferring Viral Dynamics in Chronically HCV Infected Patients from the Spatial Distribution of Infected Hepatocytes. PLoS Computational Biology, 2014, 10, e1003934.	3.2	45
47	Early microbial translocation blockade reduces SIV-mediated inflammation and viral replication. Journal of Clinical Investigation, 2014, 124, 2802-2806.	8.2	84
48	Human systems immunology: Hypothesis-based modeling and unbiased data-driven approaches. Seminars in Immunology, 2013, 25, 193-200.	5.6	28
49	Use of Laser Capture Microdissection to Map Hepatitis C Virusâ€“Positive Hepatocytes in Human Liver. Gastroenterology, 2013, 145, 1404-1413.e10.	1.3	74
50	Parameter estimation and identifiability of a HIV-1 model. , 2013, , .		0
51	Modeling the within-host dynamics of HIV infection. BMC Biology, 2013, 11, 96.	3.8	214
52	Kinetics of Coinfection with Influenza A Virus and Streptococcus pneumoniae. PLoS Pathogens, 2013, 9, e1003238.	4.7	184
53	Mechanisms Underlying CD4+ Treg Immune Regulation in the Adult: From Experiments to Models. Frontiers in Immunology, 2013, 4, 378.	4.8	63
54	Kinetics of Myeloid Dendritic Cell Trafficking and Activation: Impact on Progressive, Nonprogressive and Controlled SIV Infections. PLoS Pathogens, 2013, 9, e1003600.	4.7	32

#	Article	IF	Citations
55	The fate of CD4 + T cells under toleranceâ€inducing stimulation: a modeling perspective. Immunology and Cell Biology, 2013, 91, 652-660.	2.3	2
56	Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation Rate. PLoS Pathogens, 2012, 8, e1002881.	4.7	139
57	Elucidation of Hepatitis C Virus Transmission and Early Diversification by Single Genome Sequencing. PLoS Pathogens, 2012, 8, e1002880.	4.7	74
58	Modelling deuterium labelling of lymphocytes with temporal and/or kinetic heterogeneity. Journal of the Royal Society Interface, 2012, 9, 2191-2200.	3.4	22
59	Quantifying the activity of anti-HIV treatment in silico. Nature Medicine, 2012, 18, 355-356.	30.7	0
60	Agent-based and phylogenetic analyses reveal how HIV-1 moves between risk groups: Injecting drug users sustain the heterosexual epidemic in Latvia. Epidemics, 2012, 4, 104-116.	3.0	32
61	Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates. Blood, 2012, 120, 1357-1366.	1.4	75
62	Modeling Quasispecies and Drug Resistance in Hepatitis C Patients Treated with a Protease Inhibitor. Bulletin of Mathematical Biology, 2012, 74, 1789-1817.	1.9	38
63	Immunovirological Analyses of Chronically Simian Immunodeficiency Virus SIVmnd-1- and SIVmnd-2-Infected Mandrills (Mandrillus sphinx). Journal of Virology, 2011, 85, 13077-13087.	3.4	22
64	Evolution of Drug-Resistant Viral Populations during Interruption of Antiretroviral Therapy. Journal of Virology, 2011, 85, 6403-6415.	3.4	26
65	Functional Cure of SIVagm Infection in Rhesus Macaques Results in Complete Recovery of CD4+ T Cells and Is Reverted by CD8+ Cell Depletion. PLoS Pathogens, 2011, 7, e1002170.	4.7	82
66	Effect of 1918 PB1-F2 Expression on Influenza A Virus Infection Kinetics. PLoS Computational Biology, 2011, 7, e1001081.	3.2	67
67	Response network analysis of differential gene expression in human epithelial lung cells during avian influenza infections. BMC Bioinformatics, 2010, 11, 170.	2.6	18
68	Experimental depletion of CD8+ cells in acutely SIVagm-Infected African Green Monkeys results in increased viral replication. Retrovirology, 2010, 7, 42.	2.0	33
69	Modeling the Viral Dynamics of Influenza A Virus Infection. Critical Reviews in Immunology, 2010, 30, 291-298.	0.5	47
70	Estimation of the Initial Viral Growth Rate and Basic Reproductive Number during Acute HIV-1 Infection. Journal of Virology, 2010, 84, 6096-6102.	3.4	203
71	Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus. Science Translational Medicine, 2010, 2, 30ra32.	12.4	327
72	Viral Dynamics during Primary Simian Immunodeficiency Virus Infection: Effect of Time-Dependent Virus Infectivity. Journal of Virology, 2010, 84, 4302-4310.	3.4	48

#	Article	IF	Citations
73	Hepatitis B Virus Kinetics under Antiviral Therapy Sheds Light on Differences in Hepatitis B e Antigen Positive and Negative Infections. Journal of Infectious Diseases, 2010, 202, 1309-1318.	4.0	45
74	CD8+ Lymphocytes Control Viral Replication in SIVmac239-Infected Rhesus Macaques without Decreasing the Lifespan of Productively Infected Cells. PLoS Pathogens, 2010, 6, e1000747.	4.7	146
75	Current Estimates for HIV-1 Production Imply Rapid Viral Clearance in Lymphoid Tissues. PLoS Computational Biology, 2010, 6, e1000906.	3.2	75
76	Kinetics of Major Histocompatibility Class I Antigen Presentation in Acute Infection. Journal of Immunology, 2009, 182, 902-911.	0.8	5
77	Accelerated Immunodeficiency by Anti-CCR5 Treatment in HIV Infection. PLoS Computational Biology, 2009, 5, e1000467.	3.2	9
78	Effect of B-Cell Depletion on Viral Replication and Clinical Outcome of Simian Immunodeficiency Virus Infection in a Natural Host. Journal of Virology, 2009, 83, 10347-10357.	3.4	43
79	Modeling complex decay profiles of hepatitis B virus during antiviral therapy. Hepatology, 2009, 49, 32-38.	7.3	86
80	Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: Similar effectiveness of lamivudine, tenofovir, or combination therapy. Hepatology, 2009, 49, 1113-1121.	7.3	22
81	Divisionâ€linked differentiation can account for CD8⁺ Tâ€cell phenotype in vivo. European Journal of Immunology, 2009, 39, 67-77.	2.9	21
82	The race between infection and immunity: how do pathogens set the pace?. Trends in Immunology, 2009, 30, 61-66.	6.8	31
83	The evolutionary rate dynamically tracks changes in HIV-1 epidemics: Application of a simple method for optimizing the evolutionary rate in phylogenetic trees with longitudinal data. Epidemics, 2009, 1, 230-239.	3.0	20
84	A Mathematical Model of Hepatitis C Virus Dynamics in Patients With High Baseline Viral Loads or Advanced Liver Disease. Gastroenterology, 2009, 136, 1402-1409.	1.3	56
85	Modeling HCV kinetics under therapy using PK and PD information. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 321-332.	3.3	32
86	The level of monocyte turnover predicts disease progression in the macaque model of AIDS. Blood, 2009, 114, 2917-2925.	1.4	137
87	Limited ability of humoral immune responses in control of viremia during infection with SIVsmmD215 strain. Blood, 2009, 113, 4250-4261.	1.4	33
88	Mathematical Modeling of HCV Infection and Treatment. Methods in Molecular Biology, 2009, 510, 439-453.	0.9	19
89	Modeling amantadine treatment of influenza A virus in vitro. Journal of Theoretical Biology, 2008, 254, 439-451.	1.7	114
90	Estimating drug efficacy and viral dynamic parameters: HIV and HCV. Statistics in Medicine, 2008, 27, 4647-4657.	1.6	29

#	Article	IF	Citations
91	Modelling hepatitis C virus kinetics during treatment with pegylated interferon Î±-2b: errors in the estimation of viral kinetic parameters. Journal of Viral Hepatitis, 2008, 15, 357-362.	2.0	18
92	Modelling the kinetics of hepatitis C virus RNA decline over 4Âweeks of treatment with pegylated interferon Î±-2b. Journal of Viral Hepatitis, 2008, 15, 379-382.	2.0	13
93	The effect of early versus delayed challenge after vaccination in controlling SHIV 89.6P infection. Virology, 2008, 381, 75-80.	2.4	2
94	Simian Immunodeficiency Virus SIVagm Dynamics in African Green Monkeys. Journal of Virology, 2008, 82, 3713-3724.	3.4	101
95	Dynamics of T- and B-Lymphocyte Turnover in a Natural Host of Simian Immunodeficiency Virus. Journal of Virology, 2008, 82, 1084-1093.	3.4	42
96	The Contribution of the Thymus to the Recovery of Peripheral Naive T-Cell Numbers During Antiretroviral Treatment for HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 1-8.	2.1	26
97	Estimating the Impact of Vaccination on Acute Simian-Human Immunodeficiency Virus/Simian Immunodeficiency Virus Infections. Journal of Virology, 2008, 82, 11589-11598.	3.4	15
98	Cutting Edge: Experimentally Induced Immune Activation in Natural Hosts of Simian Immunodeficiency Virus Induces Significant Increases in Viral Replication and CD4+ T Cell Depletion. Journal of Immunology, 2008, 181, 6687-6691.	0.8	137
99	Real Time Bayesian Estimation of the Epidemic Potential of Emerging Infectious Diseases. PLoS ONE, 2008, 3, e2185.	2.5	245
100	A hepatitis C viral kinetic model that allows for time-varying drug effectiveness. Antiviral Therapy, 2008, 13, 919-26.	1.0	15
101	A Hepatitis C Viral Kinetic Model that Allows for Time-Varying Drug Effectiveness. Antiviral Therapy, 2008, 13, 919-926.	1.0	22
102	Acute Loss of Intestinal CD4+ T Cells Is Not Predictive of Simian Immunodeficiency Virus Virulence. Journal of Immunology, 2007, 179, 3035-3046.	0.8	253
103	Unequal Evolutionary Rates in the Human Immunodeficiency Virus Type 1 (HIV-1) Pandemic: the Evolutionary Rate of HIV-1 Slows Down When the Epidemic Rate Increases. Journal of Virology, 2007, 81, 10625-10635.	3.4	92
104	The role of cells refractory to productive infection in acute hepatitis B viral dynamics. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5050-5055.	7.1	101
105	Mathematical Modeling of Subgenomic Hepatitis C Virus Replication in Huh-7 Cells. Journal of Virology, 2007, 81, 750-760.	3.4	95
106	Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. Journal of Hepatology, 2007, 47, 23-30.	3.7	39
107	Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology, 2007, 46, 16-21.	7.3	115
108	Modeling the mechanisms of acute hepatitis B virus infection. Journal of Theoretical Biology, 2007, 247, 23-35.	1.7	166

#	Article	IF	Citations
109	Modeling hepatitis C virus dynamics: Liver regeneration and critical drug efficacy. Journal of Theoretical Biology, 2007, 247, 371-381.	1.7	156
110	Understanding the mechanisms and limitations of immune control of HIV. Immunological Reviews, 2007, 216, 164-175.	6.0	44
111	Dynamics of CD4 + T cells in HIVâ€1 infection. Immunology and Cell Biology, 2007, 85, 287-294.	2.3	19
112	Determining thymic output quantitatively: using models to interpret experimental Tâ€cell receptor excision circle (TREC) data. Immunological Reviews, 2007, 216, 21-34.	6.0	78
113	Towards Real Time Epidemiology: Data Assimilation, Modeling and Anomaly Detection of Health Surveillance Data Streams. Lecture Notes in Computer Science, 2007, , 79-90.	1.3	16
114	Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B. Antiviral Therapy, 2007, 12, 705-18.	1.0	18
115	Impact of Early Viral Kinetics on T-Cell Reactivity during Antiviral Therapy in Chronic Hepatitis B. Antiviral Therapy, 2007, 12, 705-718.	1.0	35
116	Pharmacodynamics of PEG-IFN Î± differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology, 2006, 43, 943-953.	7.3	81
117	Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transplantation, 2006, 12, 207-216.	2.4	73
118	Influence of Peak Viral Load on the Extent of CD4+ T-Cell Depletion in Simian HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 259-265.	2.1	37
119	NaÌ^ve and Memory Cell Turnover as Drivers of CCR5-to-CXCR4 Tropism Switch in Human Immunodeficiency Virus Type 1: Implications for Therapy. Journal of Virology, 2006, 80, 802-809.	3.4	73
120	Th-1-Type Cytotoxic CD8 + T-Lymphocyte Responses to Simian Immunodeficiency Virus (SIV) Are a Consistent Feature of Natural SIV Infection in Sooty Mangabeys. Journal of Virology, 2006, 80, 2771-2783.	3.4	57
121	MODELING THE IN VIVO DYNAMICS OF VIRAL INFECTIONS. , 2006, , .		1
122	13 Modelling the in vivo growth rate of HIV: implications for vaccination. Studies in Multidisciplinarity, 2005, , 231-246.	0.0	6
123	Impact of thymectomy on the peripheral T cell pool in rhesus macaques before and after infection with simian immunodeficiency virus. European Journal of Immunology, 2005, 35, 46-55.	2.9	40
124	High-Potency Human Immunodeficiency Virus Vaccination Leads to Delayed and Reduced CD8 + T-Cell Expansion but Improved Virus Control. Journal of Virology, 2005, 79, 10059-10062.	3.4	28
125	Hepatitis C Virus Genotype 1a NS5A Pretreatment Sequence Variation and Viral Kinetics in African American and White Patients. Journal of Infectious Diseases, 2005, 192, 1078-1087.	4.0	31
126	Mutagenic effects of ribavirin in vivo. Journal of Hepatology, 2005, 43, 553-555.	3.7	13

#	Article	IF	Citations
127	Effects of Antibody on Viral Kinetics in Simian/Human Immunodeficiency Virus Infection: Implications for Vaccination. Journal of Virology, 2004, 78, 5520-5522.	3.4	23
128	Hepatitis B Virus Kinetics and Mathematical Modeling. Seminars in Liver Disease, 2004, 24, 11-16.	3.6	37
129	Predicting the Impact of a Nonsterilizing Vaccine against Human Immunodeficiency Virus. Journal of Virology, 2004, 78, 11340-11351.	3.4	61
130	Intensification of Antiretroviral Therapy Accelerates the Decay of the HIV-1 Latent Reservoir and Decreases, But Does Not Eliminate, Ongoing Virus Replication. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 33-37.	2.1	103
131	Virus Dynamics and Immune Responses During Treatment in Patients Coinfected With Hepatitis C and HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 103-113.	2.1	26
132	Kinetics of Virus-Specific CD8 + T Cells and the Control of Human Immunodeficiency Virus Infection. Journal of Virology, 2004, 78, 10096-10103.	3.4	105
133	The Analysis of HIV Dynamics Using Mathematical Models. , 2004, , 905-912.		5
134	The life span of ganglionic glia in murine sensory ganglia estimated by uptake of bromodeoxyuridine. Experimental Neurology, 2004, 186, 99-103.	4.1	14
135	Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy. Mathematical Biosciences, 2004, 188, 47-62.	1.9	48
136	Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology, 2003, 37, 1343-1350.	7.3	175
137	Dynamics of alanine aminotransferase during hepatitis C virus treatment. Hepatology, 2003, 38, 509-517.	7.3	54
138	A sheep in wolf's clothing. Hepatology, 2003, 38, 1588-1589.	7.3	0
139	Mathematical modeling of viral kinetics:. Clinics in Liver Disease, 2003, 7, 163-178.	2.1	46
140	Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Dynamics during HCV Treatment in HCV/HIV Coinfection. Journal of Infectious Diseases, 2003, 188, 1498-1507.	4.0	99
141	Modeling Viral and Drug Kinetics: Hepatitis C Virus Treatment with Pegylated Interferon Alfa-2b. Seminars in Liver Disease, 2003, 23, 013-018.	3.6	47
142	Nonlinear partial differential equations and applications: In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: Why are CD4+ but not CD8+ T cells depleted?. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 15572-15577.	7.1	177
143	Dynamics of T Cells and TCR Excision Circles Differ After Treatment of Acute and Chronic HIV Infection. Journal of Immunology, 2002, 169, 4657-4666.	0.8	49
144	Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy. Journal of Hepatology, 2002, 37, 124-130.	3.7	36

#	Article	IF	Citations
145	Hepatitis B virus viral dynamics: effects of drug dose and baseline alanine aminotransferase. Journal of Hepatology, 2002, 37, 277-279.	3.7	5
146	Modeling Deuterated Glucose Labeling of T-lymphocytes. Bulletin of Mathematical Biology, 2002, 64, 385-405.	1.9	31
147	Dynamics of hepatitis B virus infection. Microbes and Infection, 2002, 4, 829-835.	1.9	119
148	Comparison of Different Treatment Regimens for the Emergence of New Resistance Under Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 331-335.	2.1	5
149	Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observed. Hepatology, 2001, 34, 1012-1020.	7.3	201
150	Comparison of Different Treatment Regimens for the Emergence of New Resistance Under Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 331-335.	2.1	5
151	Increased Turnover of T Lymphocytes in HIV-1 Infection and Its Reduction by Antiretroviral Therapy. Journal of Experimental Medicine, 2001, 194, 1277-1288.	8.5	329
152	Production of resistant HIV mutants during antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 7681-7686.	7.1	207
153	Virus phenotype switching and disease progression in HIVâ€1 infection. Proceedings of the Royal Society B: Biological Sciences, 1999, 266, 2523-2530.	2.6	44
154	A stochastic model for primary HIV infection: optimal timing of therapy. Aids, 1999, 13, 351-357.	2.2	33
155	The frequency of resistant mutant virus before antiviral therapy. Aids, 1998, 12, 461-465.	2.2	151